A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA

1 February 1999

journal article
Published by Springer Nature in Gene Therapy

Vol. 6 (2) , 300-304
https://doi.org/10.1038/sj.gt.3300813

Abstract

At the forefront of medicine, Gene Therapy brings you the latest research into genetic and cell-based technologies to treat disease. It also publishes Progress & Prospects reviews and News and Commentary articles, which highlight the cutting edge of the field.

Keywords

This publication has 16 references indexed in Scilit:

Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
Immunology Today, 1998
Binding Reactivity of Monoclonal Anti-Carcinoembryonic Antigen (CEA) Antibodies with Cell Membrane-Bound CEA and with Free CEA in Solution
Immunological Investigations, 1996
The T-body approach: potential for cancer immunotherapy
Springer Seminars in Immunopathology, 1996
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Proceedings of the National Academy of Sciences, 1994
Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.
The Journal of Experimental Medicine, 1993
Characterisation of a humanised bispecific monoclonal antibody for cancer therapy
British Journal of Cancer, 1993
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Proceedings of the National Academy of Sciences, 1993
Endowing T cells with antibody specificity using chimeric T cell receptors
The FASEB Journal, 1992
Carcinoembryonic Antigen
Annals of Internal Medicine, 1986
Immunohistochemical localization and molecular characteristics of three monoclonal antibody‐defined epitopes detectable on carcinoembryonic antigen (CEA)
International Journal of Cancer, 1985